Male Hypogonadism First-Line Treatment Decision Framework

What Is Male Hypogonadism and How Is It Defined?

Male hypogonadism is the failure of the testes to produce sufficient testosterone, sperm, or both. The Endocrine Society 2018 Clinical Practice Guideline defines biochemical hypogonadism as a total testosterone below 300 ng/dL confirmed on two separate morning blood draws, combined with signs and symptoms consistent with androgen deficiency. Symptoms alone are not sufficient, biochemical confirmation is mandatory before initiating any androgen therapy.

Biochemical Thresholds

The 300 ng/dL threshold comes from the 2018 Endocrine Society guideline published in the Journal of Clinical Endocrinology and Metabolism (Bhasin et al., 2018). A complementary reference is the CDC-harmonized NHANES population-based cutoff of 264 ng/dL, derived from a healthy non-obese male reference population (Travison et al., 2017, JCEM). Both values require two confirmatory morning samples because testosterone follows a diurnal rhythm, peaking between 07:00 and 10:00.

Free testosterone measurement adds diagnostic precision when total testosterone is borderline (300 to 400 ng/dL) and sex hormone-binding globulin (SHBG) may be elevated, a pattern common in older men and in obesity. The Endocrine Society guideline recommends free testosterone calculation using the Vermeulen equation rather than direct analog immunoassay, which systematically underestimates free fractions (Bhasin et al., 2018).

Classifying the Subtype Matters for Treatment

After biochemical confirmation, the clinician must classify the subtype:

• Primary hypogonadism (hypergonadotropic): elevated LH and FSH, testicular failure. Causes include Klinefelter syndrome (47,XXY), orchitis, chemotherapy, or radiation.
• Secondary hypogonadism (hypogonadotropic): low or inappropriately normal LH and FSH, hypothalamic-pituitary dysfunction. Causes include hyperprolactinemia, hemochromatosis, opioid use, obesity, or idiopathic hypogonadotropic hypogonadism (IHH).
• Mixed hypogonadism: elements of both, common in aging men (late-onset hypogonadism).

This classification directly determines treatment. Primary hypogonadism almost always requires exogenous testosterone because spermatogenesis capacity is lost. Secondary hypogonadism with intact testicular function may respond to gonadotropin stimulation, which preserves or restores fertility.

Confirming the Diagnosis: The Two-Sample Rule and Workup

Diagnosing hypogonadism correctly prevents unnecessary lifelong therapy. The minimum workup before any treatment decision includes two fasting morning total testosterone samples drawn at least one week apart, plus LH, FSH, and prolactin to classify the subtype.

Lab Panel at Diagnosis

The American Urological Association (AUA) 2018 guideline recommends the following initial panel (Mulhall et al., AUA 2018):

• Total testosterone (two separate morning samples)
• LH and FSH
• Prolactin (to exclude pituitary adenoma)
• CBC, comprehensive metabolic panel
• PSA (men over 40 or those with prostate risk factors)
• SHBG and calculated free testosterone when total T is borderline

An elevated prolactin above 200 ng/mL warrants immediate pituitary MRI before TRT initiation, as a macroprolactinoma requires dopamine agonist therapy first.

Ruling Out Reversible Causes

Secondary hypogonadism may be fully reversible. Common reversible causes that must be addressed before committing to TRT include:

• Obesity (BMI >30 suppresses testosterone via aromatization; a 10% weight loss may raise testosterone by 50 to 100 ng/dL) (Grossmann et al., Eur J Endocrinol, 2011)
• Opioid use (chronic opioids suppress LH pulsatility in 74% of men on long-term therapy) (Daniell, 2002, J Pain)
• Hemochromatosis (ferritin and transferrin saturation should be checked in secondary hypogonadism)
• Sleep apnea (nocturnal hypoxia suppresses testosterone; CPAP therapy alone raises morning testosterone by roughly 60 to 70 ng/dL in some cohorts) (Gambineri et al., 2010, JCEM)

Correcting the reversible cause first is not just preferable, the Endocrine Society guideline explicitly states it as a prerequisite before initiating TRT in secondary hypogonadism (Bhasin et al., 2018).

The First-Line Treatment Decision: TRT vs. Gonadotropin Therapy

The single most important branch point in the hypogonadism decision tree is whether the patient wants to preserve or achieve fertility. This question must be asked before any prescription is written.

Men Not Pursuing Fertility: Testosterone Replacement Therapy

For men who do not want future biological children, exogenous testosterone is the standard first-line treatment. The goal is to restore serum testosterone to the mid-normal physiological range (400 to 700 ng/dL) and relieve symptoms (Bhasin et al., 2018).

Injectable formulations are preferred first-line by most guidelines because of their established pharmacokinetics, low cost, and ease of dose adjustment:

• Testosterone cypionate: 100 to 200 mg IM or SC every 1 to 2 weeks
• Testosterone enanthate: 100 to 200 mg IM every 1 to 2 weeks
• Testosterone undecanoate (Aveed): 750 mg IM at 0, 4 weeks, then every 10 weeks, FDA-approved with a REMS program due to pulmonary oil microembolism risk (FDA Aveed label)

Topical gels (testosterone 1.62% gel, AndroGel; testosterone 2% gel, Fortesta) offer daily dosing without injection anxiety but carry a transfer risk to female partners and children, a black-box warning on all transdermal products (FDA testosterone gel labeling).

Buccal and nasal formulations (Natesto 5.5 mg intranasal TID) produce less suppression of LH and FSH than other routes, which may partially preserve spermatogenesis, a consideration in men who are uncertain about future fertility (Ramasamy et al., 2015, BJU Int).

Subcutaneous testosterone pellets (Testopel 75 mg pellets, 4 to 6 pellets every 3 to 6 months) provide stable levels but cannot be rapidly removed if adverse effects occur, making them a less flexible first choice.

Men Pursuing Fertility: Gonadotropin-Based Treatment

Exogenous testosterone suppresses the hypothalamic-pituitary axis, reducing intratesticular testosterone and shutting down spermatogenesis. In one retrospective series, 65% of men on TRT had azoospermia within 6 months (Jarow and Lipshultz, 1990, J Urol, via). For men with secondary hypogonadism who want fertility, human chorionic gonadotropin (hCG) is first-line.

HCG mimics LH, stimulates Leydig cells, and maintains intratesticular testosterone sufficient for spermatogenesis without suppressing FSH. Standard dosing is 1,500 to 3,000 IU subcutaneously three times weekly. If sperm counts remain low after 3 to 6 months of hCG monotherapy, recombinant FSH (75 to 150 IU SC three times weekly) is added.

The T-Outcomes trial and observational registry data show that hCG monotherapy normalizes testosterone in approximately 70% of men with secondary hypogonadism within 3 months (Liu et al., 2009, JCEM). For idiopathic hypogonadotropic hypogonadism, pulsatile GnRH therapy (gonadorelin via subcutaneous pump) is equally effective when available but has significant logistical challenges.

The HealthRX First-Line Decision Framework

The following decision sequence summarizes current guideline-concordant practice:

1. Confirm total testosterone <300 ng/dL on two morning samples.
2. Classify: primary vs. Secondary vs. Mixed by LH/FSH pattern.
3. Rule out reversible secondary causes (obesity, opioids, sleep apnea, hyperprolactinemia, hemochromatosis).
4. Ask fertility intent.
   • No fertility desired: initiate TRT (prefer injectable cypionate or enanthate for dose flexibility).
   • Fertility desired or uncertain: initiate hCG ± FSH; defer TRT.
5. Screen for absolute contraindications before prescribing.
6. Set monitoring milestones at 3 and 6 months.

Contraindications and Pre-Treatment Screening

TRT is contraindicated in several clinical scenarios. Prescribing without addressing these is not a minor oversight, it can precipitate prostate cancer progression or a cardiovascular event.

Absolute Contraindications to TRT

The Endocrine Society guideline lists the following absolute contraindications (Bhasin et al., 2018):

• Metastatic or locally advanced prostate cancer
• Male breast cancer
• Hematocrit above 54%
• Severe, untreated obstructive sleep apnea
• Uncontrolled heart failure
• Active desire for fertility (relative contraindication, TRT is not absolutely prohibited but should be deferred in favor of fertility-sparing therapy)

PSA above 4.0 ng/mL, or above 3.0 ng/mL in high-risk men (African American heritage, first-degree relative with prostate cancer), requires urology referral before TRT initiation. A PSA rise of more than 1.4 ng/mL in any 12-month period on TRT also requires urology evaluation.

Cardiovascular Risk: What the Evidence Actually Shows

Cardiovascular risk has been the most contentious area in TRT prescribing since a 2010 trial by Basaria et al. In the New England Journal of Medicine reported excess cardiovascular events in older, mobility-limited men receiving testosterone gel (Basaria et al., NEJM 2010). That trial enrolled a high-risk population (mean age 74, high prevalence of CVD comorbidities) and was stopped early. The results should not be generalized to healthier middle-aged men.

The TRAVERSE trial (N=5,204), published in 2023, was specifically designed to evaluate cardiovascular safety of testosterone replacement in men with hypogonadism and elevated cardiovascular risk. Testosterone undecanoate injection was non-inferior to placebo for the primary MACE endpoint (composite of cardiovascular death, nonfatal MI, nonfatal stroke) over a mean follow-up of 33 months (Lincoff et al., NEJM 2023). TRAVERSE also found a higher rate of atrial fibrillation (3.5% vs. 2.4%), pulmonary embolism (0.9% vs. 0.5%), and acute kidney injury in the testosterone arm, findings that reinforce the need for individualized risk assessment rather than blanket prescribing.

The FDA updated testosterone labeling in 2015 to require a general warning about cardiovascular risk and venous thromboembolism (FDA Drug Safety Communication, 2015). This warning remains in effect.

Monitoring After TRT Initiation

Starting TRT without a structured monitoring plan is incomplete care. The monitoring schedule should be communicated to the patient at the first prescription.

First Follow-Up at 3 Months

At 3 months after TRT initiation, check:

• Total testosterone (trough level for injections, 2 to 4 hours post-application for gels): target 400 to 700 ng/dL
• Hematocrit: hold TRT if above 54%; reduce dose or extend interval if 50 to 54%
• PSA: baseline comparison; urology referral if rise exceeds 1.4 ng/mL from pre-treatment value
• Symptom reassessment using a validated tool (ADAM questionnaire or IIEF-5 for sexual function)

If testosterone is below 400 ng/dL at trough, increase the dose by 10 to 20% or shorten the injection interval. If above 700 ng/dL, reduce dose or extend interval.

Ongoing Annual Monitoring

After stabilization, annual monitoring includes (Mulhall et al., AUA 2018):

• Total testosterone (once stable, annual checks are sufficient)
• Hematocrit (polycythemia is the most common dose-limiting adverse effect; occurs in 3 to 18% of men on TRT) (Calof et al., Meta-analysis, J Gerontol 2005)
• PSA (annually in men over 40)
• Bone mineral density (DEXA at baseline and every 1 to 2 years in men with osteoporosis or low-trauma fracture history)

Testosterone therapy does NOT require routine liver function testing when modern parenteral or transdermal formulations are used. The hepatotoxicity signal was associated with older oral 17-alpha-alkylated androgens no longer in clinical use.

Managing Erythrocytosis

Polycythemia (hematocrit >54%) is the most frequent reason TRT is interrupted. First-line management is dose reduction or interval extension. Therapeutic phlebotomy is used if symptoms of hyperviscosity (headache, plethora, visual changes) are present. Switching to a shorter-acting formulation (enanthate or cypionate) gives finer dose control than pellets or long-acting undecanoate.

Special Populations and Considerations

Older Men With Late-Onset Hypogonadism

Age-related testosterone decline is real but modest. Testosterone falls by roughly 1 to 2% per year after age 40, and the prevalence of total testosterone below 300 ng/dL rises from about 3% in men ages 30 to 39 to 18% in men ages 70 to 79 in population studies (Harman et al., J Clin Endocrinol Metab 2001). The TESTOSTERONE TRIALS (TTrials, N=790) tested TRT in older men (mean age 72) with a testosterone below 275 ng/dL. Over 12 months, testosterone gel improved sexual function scores, bone mineral density, and anemia but did not significantly improve physical function or vitality in all domains (Snyder et al., NEJM 2016). Prescribers should set realistic expectations with older patients: TRT is not a general anti-aging therapy.

Men on Chronic Opioids

Opioid-induced hypogonadism (OIH) is under-recognized. Opioids suppress GnRH pulsatility at the hypothalamic level, producing secondary hypogonadism in the majority of men on long-term opioids. Dose reduction or opioid rotation may partially restore the axis. If the opioid cannot be reduced, TRT is appropriate after the standard confirmatory workup. The AUA guideline does not list opioid use as a contraindication to TRT (Mulhall et al., AUA 2018).

Klinefelter Syndrome (47,XXY)

Klinefelter syndrome affects approximately 1 in 660 males and is the most common genetic cause of primary hypogonadism (Bonomi et al., Endocrine 2017). Most men with Klinefelter develop progressive testicular failure; testosterone production declines through adolescence and early adulthood. TRT is standard and should typically begin in mid-to-late adolescence when symptomatic androgen deficiency is confirmed. For men with Klinefelter who desire fertility, microdissection testicular sperm extraction (microTESE) combined with IVF/ICSI retrieves sperm in approximately 40 to 72% of attempts (Ramasamy et al., Fertil Steril 2009), TRT should be paused 3 to 6 months before microTESE.

Shared Decision-Making and Patient Communication

Guidelines are necessary but not sufficient. The Endocrine Society states: "We recommend that clinicians counsel patients about the benefits and risks of testosterone therapy and base treatment decisions on patient preferences, values, and comorbidities." (Bhasin et al., 2018).

What Patients Should Know Before Starting TRT

Three points require explicit discussion at every new TRT consultation:

1. TRT suppresses sperm production, men who want children in the future should know this before the first injection.
2. TRT is not a cure for the underlying cause. A man with opioid-induced hypogonadism who stops opioids may no longer need TRT.
3. TRT is a long-term commitment in most primary hypogonadism cases. Stopping abruptly after months of therapy causes symptomatic testosterone withdrawal while the HPG axis recovers, a process that can take 3 to 12 months and is not guaranteed in primary hypogonadism.

Discussing the TRAVERSE Data

Patients with established cardiovascular disease or multiple risk factors deserve a frank discussion of the TRAVERSE findings before consenting to TRT. The excess atrial fibrillation signal (3.5% vs. 2.4% in TRAVERSE, absolute difference 1.1%) should be communicated in absolute, not relative, terms (Lincoff et al., NEJM 2023).